Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus

Clinics

Volumn 67, Issue 7, 2012, Pages 711-717

  Machado, Helena Atroch ^a   Vieira, Marcelo ^a   Cunha, Maria Rosaria ^a   Correia, Marcia Regina Soares ^a   Fukui, Rosa Tsunechiro ^a   dos Santos, Rosa Ferreira ^a   Rocha, Dalva Marreiro ^a   Wajchenberg, Bernardo Leo ^a   Lage, Silvia G ^a   da Silva, Maria Elizabeth Rossi ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hemostatic factors; Metabolic profile; Treatment; Type 2 diabetes; Vascular reactivity

Indexed keywords

ANTIDIABETIC AGENT; GLIMEPIRIDE; LIPID; METFORMIN; SULFONYLUREA DERIVATIVE;

ARTICLE; BLOOD; CAROTID ARTERY; DIET RESTRICTION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGAN SIZE; PATHOLOGY; PROSPECTIVE STUDY;

BLOOD GLUCOSE; CAROTID ARTERIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; ORGAN SIZE; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS;

EID: 84867065086     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(07)03     Document Type: Article

References (40)

1. Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123(Suppl. 3):S3-S11, http://dx.doi.org/10.1016/j.amjmed.2009.12.004.
2. American Diabetes Association-Standards of medical care in diabetes. Diabetes Care. 2009;32(Suppl. 1):S13-S61.
3. Scarpello JHB, Howlett HCS. Metformin therapy and clinical uses. Diabetes and Vascular Disease Research 2008;5:157-67.
4. Bailey CJ. Metformin: Effects on micro and macro vascular complications in type 2 diabetes. Cardiovascular Drugs Ther. 2008; 22(3):215-24, http://dx.doi.org/10.1007/s10557-008-6092-0.
5. Draeger KE, Wernicke-Panten K, Lomp HJ, Schuler E, Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm Metab Res. 1996;28(9):419-25, http://dx.doi.org/10.1055/s-2007-979830.
6. Mori RC, Hirabara SM, Hirata AE, Okamoto MM, Machado UF. Glimepiride as insulin sensitizer: increased liver and muscle responses to insulin Diabetes Obes Metab. 2008l;10(7):596-600.
7. Sadikot SM, Mogensen CE. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract. 2008;82(3):391-5, http://dx.doi.org/10.1016/j.diabres.2008.09.004.
8. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006;22(6):477-82, http://dx.doi.org/10.1002/dmrr.642.
9. Bijlstra PJ, Lutterman JA, Russel FGM. Interaction of sulfonylurea derivate with vascular ATP-sensitive potassiumchannels in humans. Diabetologia. 1996;39(9):1083-90, http://dx.doi.org/10.1007/BF00400658.
10. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylureas and ischemic preconditioning. A double-blind, placebo controlled evaluation of glimepiride and glibenclamide. European Heart Journal. 1999;20(6):439-46.
11. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88(2):531-7, http://dx.doi.org/10.1210/jc.2002-020904.
12. Abbink EJ, Pickkers P, Jansen van RA, Lutterman JA, Tack CJ, Russel FG, et al. Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients. Diabet Med. 2002;19(2):136-43.
13. Spallarossa P, Schiavo M, Rossettin P, Cordone S, Olivotti L, Cordera R, et al. Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia. Diabetes Care. 2001;24(4):738-42, http://dx.doi.org/10.2337/diacare.24.4.738.
14. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45(12):1925-31, http://dx.doi.org/10.1016/j.jacc.2005.03.041.
15. Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, et al. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombinactivatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. Med Princ Pract. 2009;18(4):266-71, http://dx.doi.org/10.1159/000215722.
16. Rizzo MR, Barbieri M, Grella R, Passariello N, Paolisso G. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes Metab. 2005;31(3 Pt 1):255-60, http://dx.doi.org/10.1016/S1262-3636(07)70192-1.
17. Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr Metab. 2004;17:143-50.
18. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther. 2003;25(2):472-84, http://dx.doi.org/10.1016/S0149-2918(03)80090-5.
19. Luis BJ, Bugos C, Dirnberger G, Atherton T. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2003;25(1):194-209, http://dx.doi.org/10.1016/S0149-2918(03)90025-7.
20. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelialdependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39(2):257-65, http://dx.doi.org/10.1016/S0735-1097(01)01746-6.
21. Latt JA, Turner K. Evaluations of Trinder's glucose oxidase method for measuring glucose in serum and urine. Clin Chem. 1975;21(12):1754-60.
22. Trivelli LA, Ranney HM, Lai HT. Hemoglobin components in patients with diabetes mellitus. New Engl J Med. 1971 284:353-57.
23. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 1986;129:101-23, http://dx.doi.org/10.1016/0076-6879(86)29064-3.
24. Warnick GR, Knopp RH, Fitzpatrick V, Brauson L. Estimating lowdensity lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem. 1990;36(1):15-9.
25. Bouloux P, Perret D, Besser GM. Methodological considerations in the determination of plasma cathecolamines by high-performance liquid chromatography with electrochemical detection. Ann Clin Biochem 1985;22(Pt 2):194-203.
26. Clauss A. Rapid physiological coagulation method for determination of fibrinogen. Acta Haematol. 1957;17(4):237-46, http://dx.doi.org/10.1159/000205234.
27. Born GVR. Quantitative investigation into the aggregation of blood platelets. J Physiol. 1962;162:67-8.
28. Singer JM, Andrade DF. Analysis of longitudinal data. In Handbook of Statistics. Volume 18: Bio-Environmental and Public Health Statistics. eds. P.K. Sen and C.R. Rao. Amsterdam: North Holland.2000;115-60.
29. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. In Richard D. Irwing ed. Applied Linear Statistical Models, 4. Ed. Ilinois. 1996:1408p.
30. Meaney E, Vela A, Samaniego V, Meaney A, Asbún J, Zempoalteca JC, et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol. 2008;35(8):895-903, http://dx.doi.org/10.1111/j.1440-1681.2008.04920.x.
31. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 2007;153(3):445. e1-6, http://dx.doi.org/10.1016/j.ahj.2006.11.005.
32. Huang Z, Lei MX, Liu L, Tang QB. Effects of rosiglitazone on the IMTc and serum MMP-9 levels in newly diagnosed type 2 diabetic patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006;31(3):367-72.
33. Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H. Long term cardiovascular effects of oral antidiabetic agents in nondiabetic patients with insulin resistance: double blind, prospective, randomized study. Heart. 2005;91(5):589-94, http://dx.doi.org/10.1136/hrt.2003.027722.
34. Clark HE, Matthews DR. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non. insulin. dependent diabetes mellitus. Horm Metab Res. 1996;28(9):445-60.
35. Inoguchi T, Umeda F, Kakimoto M, Sako Y, Ishii H, Noda K, et al. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with 2 diabetes. Endocr J. 2000;47(6):763-70, http://dx.doi.org/10.1507/endocrj.47.763.
36. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest. 2007; 117(5):1226-9, http://dx.doi.org/10.1172/JCI32133.
37. Bansal P, Wang Q. Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab. 2008;295(4):E751-E761, http://dx.doi.org/10.1152/ajpendo.90295.2008.
38. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab. 2003;29(4 Pt):6S44-52, http://dx.doi.org/10.1016/S1262-3636(03)72787-6.
39. Wing LR, Hawksworth GM, Bennett B, Booth NA. Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system. J Lab Clin Med. 1991;117(2):109-14.
40. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al. For the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis. Arch Intern Med. 2010;170(21): 1892-9.